Zepbound vs Mounjaro: Same Drug, Different Labels, Which Is Right for You?
Zepbound and Mounjaro both contain tirzepatide, but their approved uses, prescriptions and payment routes differ. Compare the actual product, dose, coverage and total bill with your prescriber before choosing or switching.
By GLP-1 Picks, an independent comparison publication. Sources linked below. Our editorial policy.
Summarize this article with

In this article
- 01How much do Zepbound and Mounjaro cost?
- 02Does insurance cover Zepbound or Mounjaro?
- 03Who should get Mounjaro?
- 04Who should get Zepbound?
- 05What if neither one is covered?
- 06Why do Zepbound and Mounjaro have different names?
- 07When was each one approved?
- 08Is the dosing the same?
- 09Are the side effects the same?
- 10Can You Switch Between Mounjaro and Zepbound?
- 11Can Mounjaro be prescribed for weight loss?
- 12FAQ
- 13Sources
Both medicines contain tirzepatide, but the brand is part of a specific prescription.
The Mounjaro label covers type 2 diabetes and cardiovascular risk reduction in certain adults with type 2 diabetes.
The Zepbound label covers adult weight management and moderate-to-severe obstructive sleep apnea in adults with obesity.
The approved use, presentation and your plan rules matter; neither an identical ingredient nor a diagnosis guarantees coverage.
Which one fits you:
- •You have type 2 diabetes: ask whether Mounjaro fits your clinical needs and your plan. Its current label also includes cardiovascular risk reduction for high-risk adults with type 2 diabetes.
- •You are considering weight-management treatment: Zepbound has an adult weight-management indication. A clinician must assess suitability, and your plan must confirm coverage.
- •You are paying cash: compare the prescribed presentation and supply. LillyDirect advertises Mounjaro single-dose pens from $499 and Zepbound vials or KwikPen from $299; the higher-dose Zepbound offer has refill conditions and supplies can cost extra.
- •You have both conditions: discuss the actual diagnosis, clinical priorities, prescription and formulary with your provider. Do not change diagnostic information to obtain coverage.
- •You are comparing compounded options: use our cheapest tirzepatide guide for recorded plans and terms. Compounded products are not FDA-approved or established as equivalent to either brand.
See what each one costs and how to get it
Each page lists who prescribes it and what you pay. Your prescriber decides which one suits you.
Explore Zepbound access and costs →How much do Zepbound and Mounjaro cost?
Compare the price for the exact product and payment route. LillyDirect lists Mounjaro single-dose pens from $499 per advertised monthly supply. Zepbound vials and KwikPen have dose-dependent self-pay offers.
A savings-card quote has separate eligibility and is not a guaranteed price for every patient.
| Payment route | Mounjaro | Zepbound |
|---|---|---|
| LillyDirect self-pay | Single-dose pens from $499; prescription and terms required | Vials or KwikPen: $299 at 2.5 mg, $399 at 5 mg; $449 at 7.5–15 mg with Journey refill conditions |
| Higher-dose Zepbound offer | Separate product and payment terms | Refill within 45 days; otherwise regular $499 at 7.5 mg or $699 at 10–15 mg; supplies extra |
| Eligible covered commercial single-dose-pen savings card | As little as $25 for an eligible 1-, 2- or 3-month fill; terms and caps apply | As little as $25 for an eligible 1-, 2- or 3-month fill; terms and caps apply |
| Ordinary Medicare Part D | Qualifying prescription subject to the exact plan | Qualifying prescription subject to the exact plan |
| Medicare GLP-1 Bridge weight-management route | Not a Bridge product | KwikPen only; $50 per approved monthly supply for eligible beneficiaries |
| Medicaid | Check state, medicine and indication | Check state, medicine and indication |
Zepbound’s $299 offer is for the 2.5 mg starting dose, not maintenance; 5 mg is $399. The $449 offer for 7.5–15 mg requires refilling within 45 days under the Journey terms.
Missing that window brings the published regular price to $499 for 7.5 mg or $699 for 10–15 mg.
The offer defines a month as 28 days; required needles or syringes, taxes and fees can add to the bill. Read the exact product and refill terms before paying.
For Medicare beneficiaries, the GLP-1 Bridge program is separate from ordinary Part D and includes only Zepbound KwikPen, not its single-dose pens or vials.
Eligible patients pay $50 per monthly supply after authorization.
Mounjaro is not a Bridge product; coverage for its diabetes indication follows the individual's Part D plan. Medicare's covered products and rules.
Some telehealth platforms advertise compounded tirzepatide at $99-$199/month. These products are not FDA-approved as Mounjaro or Zepbound, are not approved generics, and have not been established by FDA as identical or equivalent.
FDA resolved the tirzepatide shortage on October 2, 2024 and shortage-based enforcement discretion ended in early 2025; any continued compounding requires a case-specific 503A or 503B and state-law analysis.
See our guides on compounded tirzepatide and cheapest tirzepatide online for current context.
Does insurance cover Zepbound or Mounjaro?
Coverage depends on your exact plan, indication and prescribed product. A medicine’s FDA approval does not require an insurer to cover it.
Check the formulary, benefit exclusions, prior authorization and your share of the bill; do not assume the same rules apply to both brands.
Your insurer’s formulary and authorization criteria determine its coverage decision.
Ask for the requirements for your actual prescription and diagnosis. Manufacturer savings terms are separate from insurance and can exclude government beneficiaries.
- •Commercial insurance, type 2 diabetes: ask whether Mounjaro is on the formulary and what authorization is needed. Do not assume Zepbound is covered under the same benefit.
- •Commercial insurance, weight management: ask whether your plan covers Zepbound for the prescribed use and whether weight-management benefits are excluded. Mounjaro does not have a weight-management indication.
- •Commercial insurance, obstructive sleep apnea: Zepbound has an indication for moderate-to-severe OSA in adults with obesity. Ask about that exact coverage route; approval and payment are not automatic.
- •Ordinary Medicare Part D: a qualifying prescription follows the individual plan’s formulary and authorization rules. This is separate from the weight-management Bridge program.
- •Medicare, weight management: Basic Part D's weight-loss exclusion remains. The separate Medicare GLP-1 Bridge launched July 1, 2026 and can provide Zepbound KwikPen at $50 per monthly supply for eligible patients. Mounjaro is not included.
- •Medicaid: check your state’s current criteria and the exact medicine; see our state-by-state guidance. A national brand comparison cannot establish state coverage.
- •Prior authorization: request your plan’s written criteria and have your prescriber submit accurate clinical information. A general BMI threshold is not proof of plan eligibility or approval.
Discuss medical suitability with your prescriber and confirm coverage with the plan or pharmacist.
If a claim is denied, ask for the reason and applicable appeal process rather than assuming another brand or diagnosis will be accepted.
Who should get Mounjaro?
- •You have type 2 diabetes and are discussing glucose control with your clinician; check the actual prescription and coverage.
- •You have type 2 diabetes and high cardiovascular risk: the current Mounjaro label includes reducing major cardiovascular events in qualifying adults.
- •Your commercial insurance formulary prefers Mounjaro over other diabetes medications (formulary preferences vary by plan)
- •You are discussing a treatment change with your prescriber. Being stable on another medicine does not establish a switching dose or guarantee a better outcome.
Who should get Zepbound?
- •Your primary diagnosis is obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related condition: this is the FDA-labeled indication
- •You have moderate-to-severe obstructive sleep apnea with obesity: Zepbound is the only tirzepatide product approved for OSA, and this indication can expand insurance coverage
- •You are comparing self-pay routes: check the exact Zepbound dose, presentation, supplies and refill deadline against the current Mounjaro quote.
- •You're on Medicare: since July 2026 the GLP-1 Bridge program covers Zepbound KwikPen at $50/month for eligible enrollees
- •Your commercial insurance covers weight-management medications and includes Zepbound on its formulary
What if neither one is covered?
Ask your prescriber about clinically appropriate alternatives your plan covers.
In SURMOUNT-5, the studied tirzepatide injections produced 20.2% average weight loss versus 13.7% with the studied semaglutide injections at 72 weeks in adults with obesity without diabetes.
Those results do not establish an individual outcome, a switching regimen, or efficacy for compounded or oral products. Our Wegovy–Zepbound comparison explains the tested regimens and limits.
For recorded program prices and payment terms, see tirzepatide providers.
The match quiz can help you compare preferences; it does not determine clinical eligibility, prescribe treatment or confirm insurance coverage.
Why do Zepbound and Mounjaro have different names?
The brands have different FDA-approved uses and prescribing information. Both contain tirzepatide, but the label for each product describes its indications, dosing and clinical evidence.
Start with the current Mounjaro and Zepbound labels.
Tirzepatide is a once-weekly injectable peptide developed by Eli Lilly.
It's the first medication to activate both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, a dual-agonist design that distinguishes it from older GLP-1-only drugs like semaglutide (sold as Ozempic, Wegovy, and Rybelsus).
For a deeper look at the two drug classes, see our semaglutide vs tirzepatide comparison.
The diabetes and obesity trial programs studied different populations and outcomes. A shared molecule does not make their trial percentages interchangeable.
The current labels identify the relevant clinical studies for each approved use.
The distinction matters when checking the prescription, device, clinical goal and insurance criteria. Do not assume one brand’s coverage or savings-card rules transfer to the other.
When was each one approved?
Key approvals and later label changes help explain the different uses:
- •May 13, 2022: Mounjaro approved for type 2 diabetes. Its current label includes glucose control in adults and children aged 10 or older, and cardiovascular risk reduction in certain high-risk adults with type 2 diabetes. These later indications should not be confused with the scope of the original approval.
- •November 8, 2023, Zepbound approved for chronic weight management. Indication: adjunct to a reduced-calorie diet and increased physical activity for long-term weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. Approval based on the SURMOUNT-1 trial showing 20.9% average weight loss at the 15 mg dose over 72 weeks.
- •December 20, 2024, Zepbound approved for obstructive sleep apnea. Indication: moderate-to-severe obstructive sleep apnea (OSA) in adults with obesity, the first drug ever approved for OSA. Approval based on the SURMOUNT-OSA trial, which showed tirzepatide reduced apnea-hypopnea index (the standard measure of OSA severity) substantially compared to placebo. This is a Zepbound-only indication; Mounjaro's label does not include OSA.
The current Mounjaro label includes diabetes-related glucose control and its specified cardiovascular indication. Zepbound covers adult weight management and moderate-to-severe OSA in adults with obesity.
The prescriber must determine clinical suitability; the insurer separately decides whether its coverage criteria are met.
Is the dosing the same?
The strengths overlap, but the indication and dose instructions still matter. The following summarizes adult label information, not a personal titration or brand-switch schedule.
Use the current Mounjaro and Zepbound labels with your prescriber; our tirzepatide dosage guide provides further context.
| Adult label feature | Mounjaro | Zepbound |
|---|---|---|
| Starting dose | 2.5 mg once weekly | 2.5 mg once weekly for 4 weeks, then 5 mg |
| Further increases | If additional glycemic control is needed: 2.5 mg increments after at least 4 weeks on the current dose | 2.5 mg increments after at least 4 weeks as appropriate; response and tolerability matter |
| Maintenance | Prescriber selects dose for clinical needs | Weight management: 5, 10 or 15 mg; OSA: 10 or 15 mg weekly |
| Maximum adult dose | 15 mg once weekly | 15 mg once weekly |
| Product/device change | Confirm the exact prescription and presentation-specific training | Confirm the exact prescription and presentation-specific training |
Zepbound’s 2.5 mg dose starts treatment; its weight-management maintenance doses are 5, 10 or 15 mg, and OSA maintenance is 10 or 15 mg. The prescriber considers response and tolerability.
Mounjaro’s pediatric maximum is lower than its adult maximum. Do not use an adult comparison table to set a child’s dose or move up automatically each month.
Are the side effects the same?
Both labels describe gastrointestinal symptoms and important risks, but their trial rates cannot be assumed identical.
The table below comes only from Zepbound’s two pooled adult weight-reduction trials, not a Mounjaro comparison: placebo N=958, 5 mg N=630, 10 mg N=948 and 15 mg N=941.
See Zepbound label §6.1 and Mounjaro label §6.1 for their separate evidence.
| Zepbound trial event | Placebo | 5 mg | 10 mg | 15 mg |
|---|---|---|---|---|
| Nausea | 8% | 25% | 29% | 28% |
| Diarrhea | 8% | 19% | 21% | 23% |
| Vomiting | 2% | 8% | 11% | 13% |
| Constipation | 5% | 17% | 14% | 11% |
| Abdominal pain | 5% | 9% | 9% | 10% |
| Permanently stopped because of adverse reactions | 3.4% | 4.8% | 6.3% | 6.7% |
For a full breakdown of side effects, management strategies, and when to call your doctor, see our Zepbound side effects guide.
Both medications carry the same FDA boxed warning about thyroid C-cell tumors (based on animal studies) and the same contraindications for patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Can You Switch Between Mounjaro and Zepbound?
A switch needs a new, clinician-managed prescription plan. Ask your prescriber and pharmacist to confirm the brand, indication, dose, timing and device, including any treatment interruption.
The labels do not establish a universal same-dose, no-washout or no-restart rule. Zepbound’s label advises against use together with another tirzepatide product or GLP-1 receptor agonist.
Do not overlap products or carry over vial-volume instructions yourself. Current Zepbound instructions and Mounjaro instructions also require training for the prescribed presentation.
Reasons to discuss a possible change include:
- •A change in clinical needs: ask which product’s approved use and evidence fit your situation.
- •Formulary change: an employer plan switches preferred tirzepatide brand mid-year
- •Self-pay: a cash-paying Mounjaro patient switches to Zepbound to access LillyDirect self-pay vials at lower cost
- •Medicare eligibility: ordinary Part D and the GLP-1 Bridge have different criteria. Turning 65 alone does not qualify a person for the Bridge or justify a brand switch.
If you're considering a switch, make that decision with your prescriber. Sprout Health's verified tirzepatide plans (2025 FDA warning for misleading compounded-drug marketing) are compounded, not Zepbound or Mounjaro; current branded availability is not confirmed.
Compare brand-name Zepbound options separately from compounded tirzepatide programs, then confirm the exact prescription, price and clinical follow-up before switching.
Can Mounjaro be prescribed for weight loss?
Weight-loss use is outside Mounjaro’s approved indications.
The FDA explains that clinicians generally may prescribe approved medicines for an unapproved use when medically appropriate.
FDA has not evaluated that unapproved use as part of the medicine’s approval. Discuss the evidence and alternatives with your clinician; an off-label decision does not establish insurance or savings-card eligibility.
Important practical consequences of off-label prescribing for tirzepatide in 2026:
- •Insurance: ask your exact plan about the prescribed use, authorization and appeals. Do not assume off-label use is covered or automatically denied.
- •Savings cards: Mounjaro’s current card requires a prescription for an approved use, along with its other product and commercial-insurance conditions. Check the exact card terms rather than assuming weight-loss use qualifies.
- •Prior authorization: the plan’s written criteria and accurate clinical documentation determine what must be submitted; the brand name alone is insufficient.
- •Clinical decision: ask the prescriber to explain the evidence, risks and alternatives for the proposed use. This article cannot decide whether an off-label prescription is appropriate for you.
This article describes how the US insurance and regulatory systems treat Mounjaro and Zepbound. It is not medical advice.
Decisions about which medication is right for you should be made with your healthcare provider based on your complete medical history, diagnosis, and treatment goals.
Never use a prescription medication outside its FDA-approved indication without your provider's guidance.
FAQ
Are Zepbound and Mounjaro actually the same drug?
Both contain tirzepatide, made by Lilly, with overlapping dose strengths. Their approved uses and presentation-specific instructions still matter.
The labels list single-dose and multi-dose presentations with different volumes; do not assume every vial, pen, formulation or injection instruction is interchangeable.
Is Zepbound better for weight loss than Mounjaro?
A shared ingredient does not establish the same weight-loss result for every patient or study population. Zepbound’s weight-management evidence and Mounjaro’s diabetes evidence have different populations and endpoints.
Use the relevant label and discuss the expected benefit for your indication with your clinician; this is not a head-to-head comparison of the brand names.
Can I use my Mounjaro Savings Card for Zepbound?
No. Savings cards are separate programs tied to a specific product, approved use, insurance status and other terms. Mounjaro’s card and Zepbound’s programs do not transfer automatically with a prescription change.
Government-beneficiary exclusions and savings limits apply.
Which one is cheaper if I'm paying cash?
Compare the exact product and dose: LillyDirect lists Mounjaro single-dose pens from $499, and Zepbound vials or KwikPen from $299 for the starting dose.
Higher-dose Zepbound’s $449 Journey price requires a refill within 45 days; regular prices and extra supplies can change the comparison. These are conditional offers, not universal all-in monthly bills.
Will Medicare cover Zepbound or Mounjaro in 2026?
Mounjaro for type 2 diabetes and Zepbound for qualifying obstructive sleep apnea can follow ordinary Part D rules, subject to the exact plan.
For weight management, the separate Bridge includes Zepbound KwikPen only, at $50 per approved monthly supply if eligible.
It excludes Mounjaro, single-dose Zepbound vials and single-dose pens. CMS distinguishes these coverage routes; our Medicare coverage guide explains the next steps.
Is compounded tirzepatide the same as Zepbound or Mounjaro?
Compounded tirzepatide is not FDA-approved as Mounjaro or Zepbound and has not been established by FDA as equivalent to either product. Its preparation, formulation and legal eligibility require separate checks.
Read our compounded tirzepatide guide; do not treat it as a brand-name generic or transfer brand trial results automatically.
Sources
- •FDA Approves Lilly's Mounjaro (tirzepatide) Injection, Eli Lilly press release, May 13, 2022
- •FDA Approves New Medication for Chronic Weight Management, FDA press release, Zepbound approval, November 8, 2023
- •FDA Approves Zepbound for Obstructive Sleep Apnea, Eli Lilly press release, December 20, 2024
- •SURMOUNT-1 Trial Results (NEJM), Zepbound obesity trial, 20.9% weight loss at 72 weeks
- •SURPASS-2 Trial Results (NEJM), Mounjaro vs semaglutide head-to-head in Type 2 diabetes
- •SURMOUNT-OSA Trial Results (NEJM), Zepbound for obstructive sleep apnea
- •Zepbound prescribing information, current manufacturer label
- •Mounjaro Cost Information, Eli Lilly 2026 pricing
- •Mounjaro Savings Resources, Eli Lilly savings card program
- •CMS GLP-1 Bridge Program, temporary Medicare GLP-1 Bridge, separate from Part D
- •Mounjaro prescribing information, current manufacturer label
- •LillyDirect Mounjaro self-pay, single-dose-pen offer and terms
- •LillyDirect Zepbound self-pay, presentation, dose, Journey refill deadline and supply costs
- •Zepbound savings terms, product-specific eligibility and exclusions
- •FDA explanation of off-label use
Medical information: this comparison does not determine treatment or insurance eligibility.
Both products carry a boxed warning based on thyroid C-cell tumors in rodents, with uncertain relevance to humans, and contraindications including personal or family MTC and MEN 2.
Discuss starting, stopping or switching with a licensed prescriber. Manufacturer offers have eligibility, supply and refill conditions and may change.
Medical disclaimer: This article is general information, not medical advice. Talk to a licensed clinician before you start, stop or change any medication. Prices and rules can change after the date we checked them.
Affiliate disclosure: Some links in this article are affiliate links. If you join a program through one, we may earn a commission at no extra cost to you.
Medicare & GLP-1
Medicare GLP-1 Coverage Guide
On Medicare? From July 1, 2026, the Medicare GLP-1 Bridge sets a $50 monthly copay for Wegovy, Zepbound and Foundayo. Our guide explains who qualifies and what it covers.
Read the Medicare guide →What the doctors say
Quotes from named doctors and medical bodies, each linked to where they said it. We did not ask for them, and they do not endorse any provider.
“So-called 'weight loss drugs' like semaglutide have proven benefits beyond reducing the number on the scales. They are now considered important medicines for preventing deadly heart attacks and strokes. Today's guidance will no doubt help save lives as cardiovascular disease is still one of the country's biggest killers.”
“While compounding can play an appropriate role when used to meet the specific needs of an individual patient, the large-scale production and marketing of compounded versions of these medicines raises serious safety risks when products have not undergone the rigorous scientific and regulatory review required for FDA-approved therapies.”
“It's not just filling out a form online and then having some random healthcare provider sign off on it. There are concerns with some of these online programs that there's not a proper evaluation, there's not a baseline, and there's not proper supervision.”
Quotes are general medical commentary about GLP-1 medications, independently sourced and not solicited by GLP-1 Picks. They are not an endorsement of any provider, our provider scores are set solely by our published methodology.